SV2011003789A - Proceso para la preparación de derivados de benzoimidazol- 2-il pirimidina - Google Patents

Proceso para la preparación de derivados de benzoimidazol- 2-il pirimidina

Info

Publication number
SV2011003789A
SV2011003789A SV2011003789A SV2011003789A SV2011003789A SV 2011003789 A SV2011003789 A SV 2011003789A SV 2011003789 A SV2011003789 A SV 2011003789A SV 2011003789 A SV2011003789 A SV 2011003789A SV 2011003789 A SV2011003789 A SV 2011003789A
Authority
SV
El Salvador
Prior art keywords
benzoimidazol
preparation
pyrimidine derivatives
pirimidin
propil
Prior art date
Application number
SV2011003789A
Other languages
English (en)
Inventor
Sergio Cesco-Cancian
Jeffrey S Grimm
Neelakandha S Mani
Christopher M Mapes
David C Palmer
Daniel J Pippel
Tong Xiao
Diego Broggini
Susanne Lochner
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011003789(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SV2011003789A publication Critical patent/SV2011003789A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LOS PROCESOS PARA LA PREPARACIÓN DE DERIVADOS DE BENZOIMIDAZOL-2-IL PIRIMIDINA ÚTILES COMO MODULADORES DEL RECEPTOR H4 DE HISTAMINA, Y UN HEMITARTRATO CRISTALINO DE [5-(4,6-DIMETIL-1H-BENZOIMIDAZOL-2-IL)-4-METIL-PIRIMIDIN-2-IL]-[3-(1-METIL-PIPERIDIN-4-IL)-PROPIL]-AMINA
SV2011003789A 2008-06-30 2011-01-03 Proceso para la preparación de derivados de benzoimidazol- 2-il pirimidina SV2011003789A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7675908P 2008-06-30 2008-06-30

Publications (1)

Publication Number Publication Date
SV2011003789A true SV2011003789A (es) 2011-04-08

Family

ID=41426846

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003789A SV2011003789A (es) 2008-06-30 2011-01-03 Proceso para la preparación de derivados de benzoimidazol- 2-il pirimidina

Country Status (27)

Country Link
US (3) US20100029942A1 (es)
EP (2) EP2865678A3 (es)
JP (2) JP2011526911A (es)
KR (1) KR20110022721A (es)
CN (2) CN102137857A (es)
AR (1) AR072397A1 (es)
AU (1) AU2009267159B2 (es)
BR (1) BRPI0913989A2 (es)
CA (1) CA2729703A1 (es)
CL (1) CL2010001639A1 (es)
CO (1) CO6341626A2 (es)
CR (1) CR20110057A (es)
EA (1) EA020090B1 (es)
EC (1) ECSP11010744A (es)
IL (1) IL210213A (es)
MX (1) MX2011000081A (es)
MY (1) MY157197A (es)
NI (1) NI201000233A (es)
NZ (2) NZ590169A (es)
PE (1) PE20140592A1 (es)
SG (1) SG192446A1 (es)
SV (1) SV2011003789A (es)
TW (2) TW201018668A (es)
UA (1) UA102855C2 (es)
UY (1) UY31951A (es)
WO (1) WO2010002777A2 (es)
ZA (1) ZA201100760B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054325B1 (ko) 2006-03-31 2011-08-04 얀센 파마슈티카 엔.브이. 히스타민 h4 수용체 조절제로서의 벤조이미다졸―2―일 피리미딘 및 피라진
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
AR072397A1 (es) 2008-06-30 2010-08-25 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de benzoimidazol-2-ilpirimidina
NZ590170A (en) * 2008-06-30 2012-04-27 Janssen Pharmaceutica Nv Process for the preparation of substituted pyrimidine derivatives
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
SG11201507117XA (en) * 2013-03-06 2015-10-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
ES2238941T3 (es) * 2000-04-24 2007-04-01 Teva Pharmaceutical Industries Ltd. Solvato de hemitartrato de zolpidem.
AU2001289701B2 (en) 2000-07-21 2004-06-24 Syngenta Participations Ag Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
TW200526637A (en) * 2003-09-30 2005-08-16 Janssen Pharmaceutica Nv Benzoimidazole compounds
JP4767857B2 (ja) * 2003-09-30 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾイミダゾール化合物
AU2005226729B2 (en) 2004-03-25 2010-01-28 Janssen Pharmaceutica N.V. Imidazole compounds
BRPI0516063A (pt) * 2004-09-27 2008-08-19 Acadia Pharm Inc sìntese de n-(4-fluorbenzil)-n-(1-metilpiperidin-4-il)-n'-(4-(2-metilp ropi-loxi)fenilmetil)carbamida e seu sal tartarato e formas cristalinas
WO2006138304A2 (en) 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
EP2004188B1 (en) * 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
KR101054325B1 (ko) * 2006-03-31 2011-08-04 얀센 파마슈티카 엔.브이. 히스타민 h4 수용체 조절제로서의 벤조이미다졸―2―일 피리미딘 및 피라진
AR072397A1 (es) 2008-06-30 2010-08-25 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de benzoimidazol-2-ilpirimidina

Also Published As

Publication number Publication date
CA2729703A1 (en) 2010-01-07
US8835633B2 (en) 2014-09-16
TW201422609A (zh) 2014-06-16
CO6341626A2 (es) 2011-11-21
IL210213A0 (en) 2011-03-31
WO2010002777A3 (en) 2010-06-24
EP2865678A3 (en) 2015-05-27
JP2014040426A (ja) 2014-03-06
IL210213A (en) 2015-08-31
MX2011000081A (es) 2011-03-02
AR072397A1 (es) 2010-08-25
SG192446A1 (en) 2013-08-30
BRPI0913989A2 (pt) 2015-10-20
NZ599747A (en) 2013-03-28
CR20110057A (es) 2013-01-25
TW201018668A (en) 2010-05-16
WO2010002777A2 (en) 2010-01-07
UA102855C2 (ru) 2013-08-27
US8921550B2 (en) 2014-12-30
US20120178932A1 (en) 2012-07-12
NI201000233A (es) 2011-11-09
JP2011526911A (ja) 2011-10-20
NZ590169A (en) 2012-05-25
EA020090B1 (ru) 2014-08-29
US20100029942A1 (en) 2010-02-04
EA201170114A1 (ru) 2011-08-30
MY157197A (en) 2016-05-13
AU2009267159A1 (en) 2010-01-07
EP2303869A2 (en) 2011-04-06
CN103319459A (zh) 2013-09-25
US20120184740A1 (en) 2012-07-19
CN102137857A (zh) 2011-07-27
EP2865678A2 (en) 2015-04-29
ZA201100760B (en) 2012-07-25
TWI485147B (zh) 2015-05-21
KR20110022721A (ko) 2011-03-07
AU2009267159B2 (en) 2014-05-15
ECSP11010744A (es) 2011-02-28
UY31951A (es) 2010-01-29
CL2010001639A1 (es) 2011-06-24
PE20140592A1 (es) 2014-05-16

Similar Documents

Publication Publication Date Title
SV2011003789A (es) Proceso para la preparación de derivados de benzoimidazol- 2-il pirimidina
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
ECSP10010390A (es) Compuestos
UY32296A (es) Nuevos compuestos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
MX2013010670A (es) Derivados de benzo [b] [1, 4] oxazina como moduldores receptores de deteccion de calcio.
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
PH12015501955A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2012002387A (es) Aminas de triazol fusionadas como moduladores p2x7.
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
NI201000232A (es) Proceso para la preparación de derivados de pirimidina sustituidos.
MX339460B (es) Derivados de benzazol como ligandos del receptor h4 de histamina.
CL2012001606A1 (es) Compuestos derivados de tiazoles bicíclicos como moduladores alostéricos de receptores mglur5; composición farmacéutica que los comprende; procedimiento de preparación de la composición farmacéutica; combinación farmacéutica; y uso del compuesto en la prevención, tratamiento o profilaxis de trastornos neurológicos o psiquiátricos.
MX345142B (es) Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina.
UY34316A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
DK2379517T3 (da) Arylcyclopropylacetamidderivater, der er anvendelige som glucokinaseaktivatorer
IT1402905B1 (it) Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
CL2010001635A1 (es) Derivados de pirimidinas utiles como moduladores del receptor h4; y su procedimiento de preparacion.
CL2010000415A1 (es) Compuestos derivados de fenil-etilen-octahidro-indol, antagonista mglur5; utiles en el tratamiento de enfermedades del snc (divisional de la solicitud cl 2764-02).